Bio SB - 2021 New Fumarate Hydratase Antibody for IHC
Bio SB is proud to announce the launch of our new Fumarate Hydratase antibody for Immunohistochemistry. Developed for Sarcoma and Soft Tissue Cancer Applications, and can be used for the diagnosis of Hereditary Leiomyomatosis and Renal cell carcinoma.
Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) is an autosomal dominant heritable syndrome with predisposition to development of Renal Cell Carcinoma and Smooth Muscle Tumors of the skin and uterus.
Cells of individuals with HLRCC had lower fumarate hydratase activity than cells from normal controls, making fumarate hydratase antibody activity testing a useful method for diagnosis and screening. Loss-of-function mutations of Fumarate Hydratase or FH predisposes individuals to the autosomal dominant syndrome of Multiple Cutaneous and Uterine Leiomyomatosis (MCUL).
Biallelic inactivation, or mutations of FH. are seen in 85% of Hereditary Leiomyomatosis and Renal Cell Carcinoma cases, 100% of Renal Cell Carcinoma with germline FH mutations, 19% of Papillary Renal Cell Carcinoma (Type II) have FH deficiency and 90% of FH deficiency RCC have FH mutations, 1% of unselected Leiomyomas, 2.6% of Leiomyomas in patients less than 40 years old and 37- 52% of Leiomyoma with bizarre nuclei.
International customers can find out more by visiting our website - https://www.biosb.com/biosb-pr....oducts/fumurate-hydr
US Customers can purchase these products directly from our eCommerce shop here - https://shop.biosb.com/fumarat....e-hydratase-bsb-151-
Bio SB performs R&D, production, distribution and marketing of unique products for Immunohistochemistry (IHC), Immunocytochemistry (ICC), Fluorescent in situ hybridization (FISH), Chromogenic in situ hybridization (CISH) and Polymerase Chain Reaction (PCR) technologies that meet the highest international standards for applications in Molecular Pathology, Cancer Research, Microbiology, Immunology and Genetics. BIO SB manufactures and develops products in accordance with FDA QSR 21 CFR Part 820 cGMP and ISO 13485:2003 standards. These guidelines enable us to produce an IVD product that meets the highest in vitro diagnostic standards.
Connect with us
๐ Visit us on: https://www.biosb.com.com/โโโโโโ
๐ Facebook: https://www.facebook.com/BioSB/โโโโโโ
๐ Twitter: https://twitter.com/Bio_SBโโโโโโ
๐ Instagram: https://www.instagram.com/biosbinc/โ
No comments found